JCR, Alexion Tie Up to Develop Oligonucleotide Therapeutics

December 21, 2023
JCR Pharmaceuticals said on December 20 that it has inked a research collaboration, option, and license accord with Alexion, the rare disease arm of AstraZeneca, for the development of novel oligonucleotide therapeutics. The deal aims to discover and develop oligonucleotide...read more